WEIGHT & METABOLISM / PEPTIDE CARD

Semaglutide

A GLP-1 receptor agonist used in FDA-approved medicines with a large randomized human evidence base.

PEPTIDE CARDSemaglutide

Reviewed
August 7, 2026

Human evidence

5/5 · Large clinical program

U.S. FDAIndication-specific approval

2026 WADANot specifically named

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

Semaglutide evidence summary.

Semaglutide has a mature evidence base, but claims must remain tied to the specific product, indication, population, and label.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

An approved active ingredient does not make every compounded or counterfeit product equivalent to an approved medicine.

01 / CLASSIFICATION

What is Semaglutide?

Entity typePeptide analog

Research categoryWeight & Metabolism

Known namesSemaglutide

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Incretin receptor agonists Goal: Weight & Metabolism Goal: Visceral Fat Research

02 / EVIDENCE

Semaglutide human and preclinical evidence.

HUMAN

5/5 · Large clinical program

Multiple large randomized programs and post-approval evidence support product-specific labeled uses.

PRECLINICAL

4/5 · Well characterized

Mechanism and nonclinical safety are extensively characterized, though clinical decisions rely on human evidence and labeling.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Semaglutide FDA and sport status.

U.S. FDAFDA approved in specific branded products and indications; compounded products are not FDA approved.

2026 WADANot specifically named in the 2026 List; athletes should still verify product ingredients.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Semaglutide being studied for?

01Type 2 diabetes

02Chronic weight management

03Cardiovascular risk

04MASH

05 / COMPARISONS

Compare Semaglutide.

Retatrutide vs SemaglutideInvestigational triple-receptor research compared with a mature GLP-1 evidence base.Tirzepatide vs SemaglutideTwo approved metabolic medicines compared without flattening product labels or trial populations.Tesamorelin vs SemaglutideA narrow HIV-lipodystrophy medicine compared with product-specific metabolic indications.AOD-9604 vs SemaglutideAn unapproved growth-hormone fragment compared with an extensively studied GLP-1 medicine.

06 / LATEST & DEFINING SOURCES

Semaglutide primary and official sources.

FDA / 2026Wegovy application and labeling record

U.S. FDA

FDA / 2026FDA concerns with unapproved GLP-1 drugs

U.S. FDA

07 / QUESTIONS

Questions about Semaglutide.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Semaglutide?

Semaglutide has a mature evidence base, but claims must remain tied to the specific product, indication, population, and label.

ResearchWhat is Semaglutide being studied for?

Current source-backed research areas include Type 2 diabetes, Chronic weight management, Cardiovascular risk, MASH. These areas describe investigation, not established personal benefit.

FDA statusIs Semaglutide FDA approved?

Current U.S. status for Semaglutide: FDA approved in specific branded products and indications; compounded products are not FDA approved.

Sport statusIs Semaglutide prohibited in sport?

Current sport-status snapshot for Semaglutide: Not specifically named in the 2026 List; athletes should still verify product ingredients.

Evidence limitsWhat are the main evidence limits for Semaglutide?

An approved active ingredient does not make every compounded or counterfeit product equivalent to an approved medicine.